Expanded enrolment for AxisBiotix-PsTM food supplement consumer study

SkinBioTherapeutics plc

(“SkinBioTherapeutics” or “the Company”)

Expanded enrolment for AxisBiotix-PsTM food supplement consumer study

  • Study size increased to 250 from 200, following high demand for places
  • Study to commence by end February 2021
  • Participants’ feedback on AxisBiotix-PsTM to be monitored through smart devices

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that AxisBiotix Limited, a wholly owned subsidiary of the Company, has increased the size of its food supplement consumer study from 200 to 250 participants, following a high level of demand.

Read more

Proposed Placing and Open Offer

SkinBioTherapeutics plc (AIM: SBTX or the “Company”) a life sciences company focused on skin health, is pleased to announce it has conditionally raised £4.0 million by way of a Placing to new and existing institutional investors.

Furthermore, to enable other Shareholders who are not able to participate in the Placing an opportunity to subscribe for new Ordinary Shares, the Company is proposing to raise up to an additional c.£0.5 million by way of an Open Offer made to Qualifying Shareholders.

» Download/view the full article

Half year results

Manchester, UK – 03 March 2020 – SkinBioTherapeutics plc (AIM: SBTX or the “Company”) a life sciences company focused on skin health, announces its unaudited half year results for the six months to 31 December 2019.

Operational and financial highlights

  • New strategy presented to shareholders, defining five pillars of development and commercial focus
  • Signed first commercial agreement in November 2019, with Croda International Plc (“Croda”), using SkinBiotix® as the foundation of an active skincare ingredient
  • Post period end, signed a development agreement around the skin-gut axis with Winclove Probiotics B.V. (“Winclove”) to create a specialist probiotic food supplement targeting psoriasis
  • Loss from operations of £889k (H1 2018: £632k) with increase due to R&D and operating expenditure
  • Cash as at 31 December 2019 £2.5m (30 June 2019: £3.1m), in line with management’s expectations

Read more